RxDoctor Payments DataLook up a doctor →

Francis Benz, MD

Neurology · Lebanon, NHNPI 1285680397

Payments from drug & device makers

$7,816in general payments, 2019–2025

Across 460 payments — averaging $16.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$930
  • Lundbeck LLC$576
  • Supernus Pharmaceuticals, Inc.$528
  • Amgen$475
  • AbbVie$473
  • Teva Pharmaceuticals USA, Inc.$388
  • plus $4K from 47 others

What the payments were for

  • Speaking & faculty fees$761%
  • Food & beverage$7,74199%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,816 in reported general payments places this provider in the 80th percentile of 92 neurology providers in New Hampshire.

See all neurology providers in New Hampshire

Medicare billing

Part B allowed, 2024
$160,272
Medicare patients
475
Services billed
6,954

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate12$59,940
Emgality PenGalcanezumab-Gnlm51$42,243
Aimovig AutoinjectorErenumab-Aooe31$39,801
Nurtec OdtRimegepant Sulfate25$37,237
QuliptaAtogepant15$17,878
NuedextaDextromethorphan Hbr/Quinidine12$17,684
RytaryCarbidopa/Levodopa12$15,557
Ajovy AutoinjectorFremanezumab-Vfrm13$11,886
Topiramate ErTopiramate19$8,825
Ajovy SyringeFremanezumab-Vfrm12$8,256
Memantine Hcl300$7,273
Divalproex Sodium ErDivalproex Sodium40$6,234
Carbidopa-LevodopaCarbidopa/Levodopa196$5,291
Levetiracetam179$5,281
Oxcarbazepine32$5,212

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$237$59,94012 claims
PfizerNurtec Odt$353$37,23725 claims
AbbVieQulipta$473$17,87815 claims
Avanir Pharmaceuticals, Inc.Nuedexta$198$17,68412 claims
Amneal Pharmaceuticals LLCRytary$196$15,55712 claims
Upsher-smith Laboratories LLCTopiramate$56$2,859195 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 92 neurology providers in New Hampshire.

Other neurology in Lebanon

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →